125 related articles for article (PubMed ID: 19687445)
1. Cytomegalovirus infection in a patient treated with efalizumab for psoriasis.
Miquel FJ; Colomina J; Maríi JI; Ortega C
Arch Dermatol; 2009 Aug; 145(8):961-2. PubMed ID: 19687445
[No Abstract] [Full Text] [Related]
2. Cytomegalovirus complicating biological immunosuppressive therapy in two patients with psoriasis receiving treatment with etanercept or efalizumab.
Petersen B; Lorentzen H
Acta Derm Venereol; 2008; 88(5):523-4. PubMed ID: 18779901
[No Abstract] [Full Text] [Related]
3. Efalizumab treatment associated with Candida colitis.
Kitagawa KH; Kalb RE
J Am Acad Dermatol; 2008 Nov; 59(5 Suppl):S120-1. PubMed ID: 19119121
[No Abstract] [Full Text] [Related]
4. A case of natural killer cell monoclonal expansion during efalizumab treatment in a patient with psoriasis.
Caproni M; Volpi W; Chiarini C; Antiga E; Giomi B; Fabbri P
Br J Dermatol; 2009 Apr; 160(4):896-7. PubMed ID: 19239461
[No Abstract] [Full Text] [Related]
5. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists.
Korman BD; Tyler KL; Korman NJ
Arch Dermatol; 2009 Aug; 145(8):937-42. PubMed ID: 19687432
[No Abstract] [Full Text] [Related]
6. Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy.
Costanzo A; Talamonti M; Spallone G; Botti E; Chimenti MS; Papoutsaki M; Chimenti S
Dermatology; 2009; 218(2):146-50. PubMed ID: 18971577
[TBL] [Abstract][Full Text] [Related]
7. Case reports: efalizumab-associated lymphoproliferative disease.
Bommakanti S; Patil A; Eshoa C; Chitambar CR
J Drugs Dermatol; 2007 Jun; 6(6):646-8. PubMed ID: 17668531
[TBL] [Abstract][Full Text] [Related]
8. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
Lebwohl M; Tyring SK; Hamilton TK; Toth D; Glazer S; Tawfik NH; Walicke P; Dummer W; Wang X; Garovoy MR; Pariser D;
N Engl J Med; 2003 Nov; 349(21):2004-13. PubMed ID: 14627785
[TBL] [Abstract][Full Text] [Related]
9. Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice.
Puig L; Roé E; García-Navarro X; Corella F; Alomar A
Clin Exp Dermatol; 2009 Jun; 34(4):469-75. PubMed ID: 19077105
[TBL] [Abstract][Full Text] [Related]
10. Exacerbation of psoriasis under efalizumab therapy.
Rallis E; Verros C; Karanikola E; Valaskatzi A; Papaconstantis M
J Cutan Med Surg; 2009; 13(2):106-9. PubMed ID: 19298780
[TBL] [Abstract][Full Text] [Related]
11. Urticaria associated with hyper-IgE in a patient with psoriasis undergoing treatment with efalizumab.
Saraceno R; Scotto G; Chiricozzi A; Chimenti S
Acta Derm Venereol; 2009; 89(4):412-3. PubMed ID: 19688158
[No Abstract] [Full Text] [Related]
12. Efalizumab-induced thrombocytopenia: report of relapse after re-administration.
Kiorpelidou D; Tsiouri G; Gaitanis G; Akritidis N; Bassukas ID
Clin Exp Dermatol; 2009 Dec; 34(8):e914-6. PubMed ID: 20055866
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment of plaque psoriasis with efalizumab: an Italian experience.
Costanzo A; Peris K; Talamonti M; Di Cesare A; Fargnoli MC; Botti E; Chimenti S
Br J Dermatol; 2007 Apr; 156 Suppl 2():17-23. PubMed ID: 17371319
[TBL] [Abstract][Full Text] [Related]
14. Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute.
Ferrándiz C; Carrascosa JM
Br J Dermatol; 2007 Apr; 156 Suppl 2():24-9. PubMed ID: 17371320
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.
Costanzo A; Talamonti M; Botti E; Spallone G; Papoutsaki M; Chimenti S
Dermatology; 2009; 219(1):48-53. PubMed ID: 19372639
[TBL] [Abstract][Full Text] [Related]
16. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
[TBL] [Abstract][Full Text] [Related]
17. Comment on "Development of monoclonal gammopathy in 12 patients receiving efalizumab treatment for chronic plaque psoriasis".
Ginarte M
J Am Acad Dermatol; 2011 Jun; 64(6):1184; author reply 1184-5. PubMed ID: 21571182
[No Abstract] [Full Text] [Related]
18. Disseminated eruptive giant mollusca contagiosa in an adult psoriasis patient during efalizumab therapy.
Weisenseel P; Kuznetsov AV; Flaig M; Prinz JC
Dermatology; 2008; 217(1):85-6. PubMed ID: 18446030
[TBL] [Abstract][Full Text] [Related]
19. Lymphomatoid papulosis while on efalizumab.
Leo AM; Ermolovich T
J Am Acad Dermatol; 2009 Sep; 61(3):540-1. PubMed ID: 19700027
[No Abstract] [Full Text] [Related]
20. Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome.
Driessen RJ; Berends MA; Boezeman JB; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2008 May; 158(5):1098-106. PubMed ID: 18384440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
